ClinicalTrials.gg
RecruitingNCT06758024PROMPT-IBDUpdated Nov 12, 2026

PROactive and Early Infliximab Monitoring and oPTimization in Inflammatory Bowel Disease

An interventional study of Infliximab and Infliximab in Inflammatory Bowel Disease (IBD), Crohn Disease (CD) and Ulcerative Colitis (UC), sponsored by Pontificia Universidad Catolica de Chile. Recruiting at 1 site in Chile. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Pontificia Universidad Catolica de Chile · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Nov 12, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing infliximab in Inflammatory Bowel Diseases — 6 open to participants now, 7 under way, none of them phase 3. Infliximab · Inflammatory Bowel Diseases.

Planned enrollment
12th of 20
72 · median 83
Started
2025
with 1 other
No phase
4 of 20
1 open now
Registered
19th of 20
by date

Among the 20 studies testing infliximab in Inflammatory Bowel Diseases, this one is the 12th largest by planned enrollment, is one of 2 that started in 2025, is one of 4 with no phase, and was the 19th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

6 of the 20 studies testing infliximab in Inflammatory Bowel Diseases are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About infliximab

Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing infliximab in Inflammatory Bowel Diseases, or all of them as a file.
02

Study summary

Infliximab (IFX) is a Food and Drug administration (FDA)-appoved monoclonal antibody medication targeting tumor necrosis factor (TNF) widely used in inflammatory bowel disease (IBD) to treat intestinal inflammation and improve patient's symptoms. Intravenous (iv) IFX is effective to treat hospitalized IBD patients with moderate-to-severe flares who fail iv corticosteroids (CS). However, about one-third of IBD patients do not respond to this medications and a half will loss the response after an initial response. Researchers have shown that most of these phenomena occur due to low IFX concentrations sometimes accompanied by the development of anti-drug antiboides (ADA) againts IFX.

Blood concentrations of IFX are widely variable among IBD patients despite receiving the same weight-based dose. Several patient factors including laboratory parameters and severity of intestinal inflammation influence the way an individual's body proccesses and eliminate this type of medications. Dashboard software systems can take into account patient characteristics and IFX concentrations to modelate and facilitate dosing of IFX. By using pharmacokinetics (PK) models specifically developed to facilitate IFX dosing, these softwares can provide and recommend multiple dosing regimes to help the clinicians to select the appropriate dose to achieve target and optimal IFX concentrations.

The goal of this clinical trial is to learn if early measuring of IFX blood concentrations and dashboard-guided IFX dose adjustment in Chilean IBD patients starting IFX, increases the proportion of patients with optimal IFX levels and improves patient outcomes. Researchers will measure IFX concentrations before the second (week 2) and third dose (week 6) in a prospectively collected individual patient cohort and this information along with clinical data will be analyzed with a dashboard software system and multiple dosing regime options will be provide to the attending clinicians to facilitate the selection of the next IFX weight-based dose and interval of infusions. This group will be compared with IBD patients with standard of dosing where attending clinicians make the dosing decisions based on clinical parameters. The main goal is to analyze if IBD patients in the dashboard-guided dosing arm achieve a higher proportion of optimal IFX concentrations at week 14 of treatment, develop ADA less frequently and improve clinical outcomes compared with standard dosing group.

Participants will be asked to:

  • Provide clinical data about their disease and other conditions
  • Provide blood samples at enrollment and before each IFX infusion (IFN) during one year
  • Maintain regular clinical assessments every 3 months for one year
Read the detailed description

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are chronic diseases that entail important morbidity and frequently require high-cost medications such as biologic therapies. Monoclonal antibodies against tumoral necrosis factor (anti-TNF) are effective and can modify the progressive course of IBD. In Chile, given the high cost of anti-TNF therapy, this medication is provided by a national program with universal coverage. Unfortunately, a significant proportion of IBD patients never respond (primary non-response, PNR) or experience loss of response (secondary loss of response, SLR) to anti-TNF within the first year of therapy and current evidence support that the complex pharmacokinetics of anti-TNF is involved in both scenarios. Additionally, low trough levels (TL) are associated with the development of antidrug antibodies (ADA) which reduce anti-TNF efficacy and can cause anaphylactic reactions. This is particularly relevant for intravenous infliximab (IFX) which is usually indicated in IBD patients with acute severe disease not responding to iv corticosteroids. Therefore, IFX is frequently dose escalated in patients based on clinical parameters that are thought to be related to drug clearance with conflicting evidence supporting this strategy. Several studies have demonstrated that IFX TL between 7-20 mcg/ml at week 14 of treatment is a strong and independent predictor of therapy response. Furthermore, IFX dashboard-guided dose optimization based on clinical and pharmacokinetic (PK) parameters using adaptive Bayesian modeling have demonstrated to be more precise that empirical adjustments based on the clinician intuition alone. Therefore, the goal of this study is to analyze whether early therapeutic drug monitoring (TDM) and dose adjustment based on a Bayesian model (iDOSE) in CD and UC patients initiating IFX, increases the proportion of patients with therapeutic levels (7-20 mcg/ml), reducing immunogenicity and consequently increasing the rate of disease remission. A prospective multicentric randomized clinical trial (RCT) of Chilean adult IBD inpatients starting IFX due to moderate-to-severe disease refractory to corticosteroids will be carried out. Patients will be randomized 1:1 to:

  1. - Dashboard-guided dosing arm. Patients will undergo proactive TDM during induction (TL at IFN 2 and 3) with dose adjustment based on iDOSE.
  2. - Standard dosing arm. Patients will receive dose adjustment based solely on clinical parameters.

Both groups will be followed-up after induction with clinical visits, TL and ADA at week 14 (INF 4), 26 and 52. Researchers expect that a higher proportion of patients in the dashboard-guided dosing arm will achieve therapeutic TL of IFX (7-20 mcg/ml) at week 14 of treatment (Primary outome). Secondary outcomes will include clinical and laboratory parameters related to therapy response at week 52 of treatment, proportion of patients experiencing PNR and SLR, patients developing ADA, as well as, adverse events, hospitalization and surgery

03

Conditions studied

  • Inflammatory Bowel Disease (IBD)
  • Crohn Disease (CD)
  • Ulcerative Colitis (UC)

Keywords

  • Inflammatory Bowel Disease
  • Infliximab
  • dashboard-guided dosing
  • therapeutic drug monitoring
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult inpatients with Crohn's disease, ulcerative colitis or inflammatory bowel disease-unclassified.
  • Moderate-to-severe flare who fail to iv and require infliximab as per standard of care by treating gastroenterologist

Exclusion criteria

Exclusion Criteria:

  • Participant younger than 18 years
  • Non-controlled infectious diseases
  • Permanent ileostomy or Ileal pouch-anal anastomosis
  • Pregnancy
  • Patients do not consent to participate in study
  • Patients unable to comply with protocol
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Other
    Dashboad-guided dosing

    Eligible patients will receive IFX with proactive therapeutic drug monitoring during induction (week 2 and 6) and dashboard-guided dosing options will be suggested to their attending gastroenterologists

    Drug: Infliximab

  • Other
    Standard dosing

    Eligible patients will receive IFX standard dosing during induction based solely on clinical data

    Drug: Infliximab

Interventions

  • IFX therapeutic drug monitoring before the second and third infusion and subsequent dashboard-guided dosing regimes suggested to attending gastroenterologists based on clinical and pharmacokinetics data

  • No IFX therapeutic drug monitoring before the second and third infusion and subsequent dosing regimes based on clinical data

06

What researchers measure

Primary outcomes

  1. Infliximab optimal concentration

    Proportion of patients who achieve infliximab trough levels between 7-20 mcg/ml at week 14 of treatment

    Time frame: Week 14

Secondary outcomes

  1. Clinical remission

    Proportion of subjects in clinical remission at week 52 (CDAI \<150 for CD or partial Mayo score \< 2 for UC).

    Time frame: Week 52

  2. Corticosteroid-free clinical remission

    Proportion of subjects in Corticosteroid (CS)-free clinical remission at week 52 (CDAI \<150 for CD or partial Mayo score \< 2 for UC and no use of CS within previous 6 months).

    Time frame: Week 52

  3. Sustained corticosteroid-free clinical remission

    Proportion of subjects with sustained CS-free clinical remission at week 52 (CDAI \<150 for CD or partial Mayo score \< 2 for UC and no CS use from week 14 through week 52).

    Time frame: Week 52

  4. CRP normalization

    Proportion of subjects with normalisation of C-reactive protein (CRP) at week 52 (decrease from ≥1 at baseline to \<1 mg/dL).

    Time frame: Week 52

  5. Fecal calprotectin normalization

    Proportion of subjects with normalisation of fecal calprotectin at week 52 (decrease from \>250μg/g at baseline to ≤250mcg/g).

    Time frame: Week 52

  6. Primary non-response

    Proportion of subjects who are primary non-responders (≤70-point decrease in CDAI score for CD or decrease in partial Mayo score of ≥2 points and ≥25% for UC from baseline) and at least one of: CRP ≥1mg/dL or FC \>250μg/g; or need for rescue therapy prior to week 14).

    Time frame: Week 14

  7. Secondary loss of response

    Proportion of subjects exhibiting secondary loss of response (CDAI \>220 or partial Mayo score \>4 and at least one of: CRP ≥1mg/dL or FC \>250μg/g; or need for rescue therapy) during maintenance.

    Time frame: Week 14 through 52

  8. Antibodies to infliximab-free survival

    Proportion of subjects with no antibodies to infliximab (ATI).

    Time frame: Week 2 through 52

  9. Proportion of subjetcs with antibodies to infliximab

    Proportion of subjects with antibodies to infliximab (ATI)

    Time frame: Week 2 through 52

  10. Time to antibodies to infliximab

    Time to antibodies to infliximab (ATI) development.

    Time frame: Week 2 through 52

  11. Adverse events

    Proportion of subjects with any treatment-related adverse event.

    Time frame: Week 0 through 52

  12. Surgery

    Proportion of subjects with CD or UC-related surgery

    Time frame: Week 0 through 52

  13. Time to surgery

    Time to CD or UC-related surgery

    Time frame: Week 0 through 52

  14. Hospitalization

    Proportion of subjects with CD or UC-related hospitalisation.

    Time frame: Week 0 through 52

  15. Time to hospitalization

    Time to CD or UC-related hospitalisation

    Time frame: Week 0 through 52

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Mar 2027, 26 months after the start.

Of 285 non-industry interventional studies with no phase under Inflammatory Bowel Diseases, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 26 months is close to that.

Counting every sponsor, half of 299 studies reached it within 26 months; a quarter within 14 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jan 2026 → Mar 2027 and completion Jan 2027 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2024
First posted
Jan 3, 2025
StartActual
Jan 24, 2025
Primary completionEst.
Mar 2027was Jan 2026
CompletionEst.
Jan 2028was Jan 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 2026→Mar 2027
Nov 12, 2026
Study completion
Jan 2027→Jan 2028
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Primary completion Jan 2026→Mar 2027
    Study completion Jan 2027→Jan 2028
    + 4 other changes: identifiers, verification date, oversight details and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06758024
Collaborators
Clínica Universidad de los Andes, Hospital San Juan de Dios,Chile, University of Chile, Clinica Indisa, Universidad de La Frontera
Responsible party
Sponsor
First posted
Jan 3, 2025
Start date
Jan 24, 2025
Primary completion
Mar 2027 (estimated)
Completion
Jan 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Cristian Hernández-Rocha Cristian Hernández-Rocha, MD
Contact
caherna4@uc.cl
56-22-3543838
Carolina Pavez Carolina Pavez, MD
Contact
cdpavez@uc.cl
56-22-3543838

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infliximab

Start the discussion